1. He Y, Pei Y, Liu K, Liu L, Tian Y, Li H, Cong M, Liu T, Ma H, You H, Jia J*, Zhang D*, Wang P*. GITR/GITRL reverse signalling modulates the proliferation of hepatic progenitor cells by recruiting ANXA2 to phosphorylate ERK1/2 and Akt.Cell Death Dis.2022.13(4).297.SCI |
2. Wang P, Cui Y, Wang J, Liu D, Tian Y, Liu K, Wang X, Liu L, He Y, Pei Y, Li L, Sun L, Zhu Z, Chang D*, Jia J*, You H*.Mesenchymal stem cells protect against acetaminophen hepatotoxicity by secreting regenerative cytokine hepatocyte growth factor .Stem Cell Res Ther.2022.13(1).94.SCI |
3. Wang Q, Zhao H, Deng Y, Zheng H, Xiang H, Nan Y, Hu J, Meng Q, Xu X, Fang J, Xu J, Wang X, You H, Pan CQ, Xie W*, Jia J*.Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis.J Hepatol.2022.77(6).1564-1572.SCI |
4. Lv T, Jia J*.Rare liver diseases are not rare in China.Liver Int.2022.42(9).2023-2028 .SCI |
5. An W, Wu Z, Li M, Yu H, Zhao X, Wang X, Wang Y, Wang Q, Duan W, Kong Y, Ma H, Ou X, You H, Liu Y, Li P, Duan T, Jia J*.Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.Orphanet J Rare Dis.2022.17(1).307 .SCI |
6. Shan S, Jia JD*.Adenovirus and severe acute hepatitis of unknown etiology in children: Offender or bystander? .Hepatobiliary Pancreat Dis Int.2022.21(4).354-355.SCI |
7. Zhang W, Li Y, Xu A, Ouyang Q, Wu L, Zhou D, Wu L, Zhang B, Zhao X, Wang Y, Wang X, Duan W, Wang Q, You H, Huang J*, Ou X*, Jia J*.China Registry of Genetic/Metabolic Liver Diseases (CR-GMLD) Group. Identification of novel non-HFE mutations in Chinese patients with hereditary hemochromatosis.Orphanet J Rare Dis.2022.17(1).216.SCI |
8. Chen S, Lv T, Sun G, Li S, Duan W, Zhang C, Jin H, Tian D, Li M, Shan S, Ma H, Ou X, You H, Zhang D*, Jia J*.Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis. Hepatol Int.2022.16(1).195-206.SCI |
9. 黄樱硕,赵连晖,魏巍,左旭,单姗,马红,汪颖,崔焱,尤红,卢鸣,董瑞华*,贾继东*.药物临床试验电子知情同意及受试者补助电子发放技术的满意度评价.临床和实验医学杂志.2021.20(21).2349-2353.核心期刊 |
10. 中华医学会肝病学分会,贾继东*,徐小元*.慢性肝病、肝脏恶性肿瘤及肝移植患者新型冠状病毒疫苗接种快速指南.中华肝脏病杂志.2021.29(6).523-526 .核心期刊 |
11. 贾继东,牛俊奇,尤红,孔媛媛,侯金林.2020年慢性乙型肝炎治疗和新药临床研究进展.中华肝脏病杂志.2021.29(2).97-101.核心期刊 |
12. Wu L, Zhang W, Li Y, Zhou D, Zhang B, Xu A, Wu Z, Wu L, Li S, Wang X, Zhao X, Wang Q, Li M, Wang Y, You H, Huang J*, Ou X*, Jia J*.Correlation of genotype and phenotype in 32 patients with hereditary hemochromatosis in China.Orphanet Journal of Rare Diseases.2021.16(1).398.SCI |
13. 黄樱硕,崔焱,单姗,赵连晖,左旭,马红,尤红,付小龙,郭子婕,卢鸣,董瑞华,贾继东*.药物临床试验电子知情同意及受试者补助电子发放的实施探索 .中国新药杂志 .2021.30(18).1698-1702.核心期刊 |
14. 李敏,苏健婷,武珊珊,韦在华,孔媛媛,贾继东*.乙型肝炎肝硬化患者年龄和性别与肝病相关死亡风险的关系.中华肝脏病杂志.2021.29(5).403-408.核心期刊 |
15. 单姗,赵连晖,马红,欧晓娟,尤红,贾继东*.肝硬化的定义、病因及流行病学.临床肝胆病杂志.2021.37(1).14-16.核心期刊 |
16. Tian Q, Yang R, Wang Y, Liu J, Wee A, Saxena R, Wang L, Li M, Liu L, Shan S, Kong Y, Ma H, Ou X, You H, Zhao X*, Jia J*..A High Serum Level of Taurocholic Acid is Correlated with the Severity and Resolution of Drug-induced Liver Injury .Clinical Gastroenterology and Hepatology.2021.19(5).1009-1019.SCI |
17. Wu X, Zhou J, Sun Y, Ding H, Chen G, Xie W, Piao H, Xu X, Jiang W, Ma H, Ma A, Chen Y, Xu M, Cheng J, Xu Y, Meng T, Wang B, Chen S, Shi Y, Kong Y, Ou X*, You H*, Jia J*..Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.Hepatology International.2021.15(1).82-92.SCI |
18. an R, Niu J, Ma H, Xie Q, Cheng J, Rao H, Dou X, Xie J, Zhao W, Peng J, Gao Z, Gao H, Chen X, Chen J, Li Q, Tang H, Zhang Z, Ren H, Cheng M, Liang X, Zhu C, Wei L, Jia J*, Sun J*, Hou J*.Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therap.ALIMENTARY PHARMACOLOGY & THERAPEUTICS.2021.54(3).329-338.SCI |
19. Fan X, Shan S, Wu P, Lin W, Jia J*, He F*.Irradiated and CCl4‐treated bone marrow‐derived liver macrophages exhibit different gene expression patterns and phenotypes.Scandinavian journal of immunology.2020.92(5).e12916.SCI |
20. Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, Liu H, Wang T, Zhao X, Wu S, Kong Y, Ou X, Wee A, Theise ND, Qiu C, Zhang W, Lu F, Jia J*, You H*.Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy.Clinical Gastroenterology and Hepatology.2020.18(11).2582-2591.SCI |
21. Zhang C, Jin H, Wang Y, Li C, Zhao X, Li Y, Shi W, Tian Y, Xu H, Tian D, Liu K, Jia J*, Sun G*, Zhang D*..Critical role of OX40 in drug-induced acute liver injury.British Journal of Pharmacology.2020.117(14).3183-3196.SCI |
22. 中国医师协会消化医师分会,中华医学会肝病学分会,魏来*,贾继东*.新型冠状病毒肺炎合并肝脏损伤的预防及诊疗方案.中华肝脏病杂志.2020.28(3):.217-221.核心期刊 |
23. Li M, Lv T, Wu S, Wei W, Wu X, Ou X, Ma H, Chow SC, Kong Y*, You H*, Jia J*. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis.Hepatology International.2020.14(1).105-114.SCI |
24. Wu L, Li Y, Song Y, Zhou D, Jia S, Xu A, Zhang W, You H, Jia J*, Huang J*, Ou X*. A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China . Orphanet journal of rare diseases.2020.15(1).74.SCI |
25. Cong M, Ou X, Huang J, Long J, Li T, Liu X, Wang Y, Wu X, Zhou J, Sun Y, Shang Q, Chen G, Ma H, Xie W, Piao H, Yang Y, Gao Z, Xu X, Tan Z, Chen C, Zeng N, Wu S, Kong Y, Liu T, Wang P, You H*, Jia J*, Zhuang H*.A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus.Omics : a journal of integrative biology.2020.198(4).263-9.SCI |
26. Zhang W, Wang X, Duan W, Xu A, Zhao X, Huang J, You H, Brissot P, Ou X*, Jia J*.HFE-Related Hemochromatosis in a Chinese Patient: The First Reported Case.Frontiers in genetics.2020.11.77.SCI |
27. Wang P, Cong M, Liu T, Li Y, Liu L, Sun S, Sun L, Zhu Z, Ma H, You H*, Zhang H*, Jia J*.FoxA2 inhibits the proliferation of hepatic progenitor cells by reducing PI3K/Akt/HK2-mediated glycolysis.Journal of cellular physiology.2020.235(12).9524-9537.SCI |
28. Zhang C, Jin H, Wang Y, Li C, Zhao X, Li Y, Shi W, Tian Y, Xu H, Tian D, Liu K, Jia J*, Sun G*, Zhang D*.Critical role of OX40 in drug-induced acute liver injury.British journal of pharmacology.2020.177(14).3183-3196.SCI |
29. Shan S, Wei W, Kong Y, Niu J, Shang J, Xie W, Zhang Y, Ren H, Tang H, Ding H, Nan Y, Dou X, Han T, Xu X, Duan Z, Wei L, Hou J, Zhuang H, You H*, Jia J*.China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B.Scandinavian journal of public health .2020.48(2).233–239.SCI |
30. Duan WJ, Wang XZ, Ma AL, Shang J, Nan YM, Gao ZL, Tang H, Fu QC, Xie Q, Mao Q, Niu JQ, Han T, Li J, Han Y, Cao JB, Kong YY, Shi XY, Lv FD, Wang TL, Ma H, You H, Ou XJ*, Jia JD*..Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B. Journal of digestive diseases.2020.21(9).519–525.SCI |
31. 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会,陆伦根*,尤红*,谢渭芬*,贾继东*.肝纤维化诊断及治疗共识(2019年).中华肝脏病杂志.2019.27(9).657-667.核心期刊 |
32. Wang Y, Wang L, Saxena R, Wee A, Yang R, Tian Q, Zhang J, Zhao X*, Jia J*.Clinicopathological features of He Shou Wu-induced liver injury: This ancient anti-aging therapy is not liver-friendly.Liver International.2019.39(2).389-400.SCI |
33. Chen S, Duan W, Li M, Li S, Lv T, Tian Q, Wang Q, Wu X, Zhao X, Wang X, Wang Y, Kong Y, Ma H, Ou X, You H, Jia J*.Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.Journal of Gastroenterology and Hepatology.2019.34(7).1236-1241.SCI |
34. Fan W, Liu T, Chen W, Hammad S, Longerich T, Hausser I, Fu Y, Li N, He Y, Liu C, Zhang Y, Lian Q, Zhao X, Yan C, Li L, Yi C, Ling Z, Ma L, Zhao X, Xu H, Wang P, Cong M, You H, Liu Z, Wang Y, Chen J, Li D, Hui L, Dooley S*, Hou J*, Jia J*, Sun B*.ECM1 Prevents Activation of Transforming Growth Factor beta, Hepatic Stellate Cells, and Fibrogenesis in Mice.Gastroenterology.2019.157(5).1352-1367.SCI |
35. Wang T*, Zhao X, Shao C, Ye L, Guo J, Peng N, Zhang H, Li J, Kong Y, You H*, Jia J*.A proposed pathologic sub-classification of drug-induced liver injury.Hepatology International.2019.13(3).339-351.SCI |
36. Zeng N, Duan W, Chen S, Wu S, Ma H, Ou X, You H, Kong Y*, Jia J*.Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.Hepatology International.2019.13(6).788-799.SCI |
37. 赵新颜,何志颖,刘立伟,黄坚,孙丽莹,欧晓娟,贾继东*.45例原发性与继发性血色病临床病理特点对比研究 .传染病信息.2019.32(2).127-131.核心期刊 |
38. Kong Y, Sun Y, Zhou J, Wu X, Chen Y, Piao H, Lu L, Ding H, Nan Y, Jiang W, Xu Y, Xie W, Li H, Feng B, Shi G, Chen G, Li H, Zheng H, Cheng J, Wang T, Liu H, Lv F, Shao C, Mao Y, Sun J, Chen T, Han T, Han Y, Wang L, Ou X, Zhang H, Jia J*, You H*.Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.Journal of Viral Hepatitis.2019.26(5).1499-1509.SCI |
39. 张伟,黄坚,欧晓娟,尤红,贾继东*.血色病国际有关HFE p.Cys282Tyr纯合基因型血色病的治疗推荐意见.中华肝脏病杂志.2019.27(12).980-981.核心期刊 |
40. Wang Q, You H, Ou X, Zhao X, Sun Y, Wang M, Wang P, Wang Y, Duan W, Wang X, Wu S, Kong Y, Saxena R*, Gouw ASH*, Jia J*.Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis.Hepatology International.2019.13(6).766-776.SCI |
41. Wu X, Zhou J, Xie W, Ding H, Ou X, Chen G, Ma A, Xu X, Ma H, Xu Y, Liu X, Meng T, Wang L, Sun Y, Wang B, Kong Y, Ma H, You H*, Jia J*.Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study..Expert Rev Anti Infect Ther .2019.12.745-757.SCI |
42. Li M, Kong YY, Wu SS, Zhou JL, Wu XN, Wang L, Su JT, Ou XJ, You H, Xie XQ, Wei ZH*, Jia JD*.Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China.Journal of digestive diseases.2019.20(9).467–475.SCI |
43. Lv T, Li M, Zeng N, Zhang J, Li S, Chen S, Zhang C, Shan S, Duan W, Wang Q, Wu S, You H, Ou X, Ma H, Zhang D, Kong Y*, Jia J*.Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population.Journal of gastroenterology and hepatology.2019.34(10).1676-1684.SCI |
44. Zhang W, Zhao X, Huang J, Ou X*, Jia J*.Alagille syndrome: an uncommon cause of intrahepatic cholestasis in adults.Revista espanola de enfermedades digestivas.2019.111(4).323-326.SCI |
45. Tian QJ, Zhao XY, Wang Y, Wee A, Soon GST, Gouw ASH, Li M, Yang RY, Wang L, Wang QY, Duan WJ, Wang Y, Wang XM, Kong YY, Ou XJ, You H, Jia JD*.Histologic pattern is better correlated with clinical outcomes than biochemical classification in patients with drug-induced liver injury.Modern pathology.2019.32(12).1795–1805.SCI |
46. Li X, Zhang W, Zhou D, Lv T, Xu A, Wang H, Zhao X, Zhang B, Li Y, Jia S, Wang Y, Wang X, Wu Z, Duan W, Wang Q, Nan Y, Shang J, Jiang W, Chen Y, Zheng S, Liu M, Sun L, You H, Jia J*, Ou X*, Huang J*.Complex ATP7B mutation patterns in Wilson disease and evaluation of a yeast model for functional analysis of variants.Human mutation.2019.40(5).552–565.SCI |
47. Zhang W, Xu A, Li Y, Zhao S, Zhou D, Wu L, Zhang B, Zhao X, Wang Y, Wang X, Duan W, Wang Q, Nan Y, You H, Jia J*, Ou X*, Huang J*.A novel SLC40A1 p.Y333H mutation with gain of function of ferroportin: A recurrent cause of haemochromatosis in China.Liver International.2019.39(6).1120-1127.SCI |
48. He T, Bai Y, Cai H, Ou X, Liu M, Yi W*, Jia J*.Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B.Hepatology International.2018.12(2).118-125.SCI |
49. Lv T, Zhang W, Xu A, Li Y, Zhou D, Zhang B, Li X, Zhao X, Wang Y, Wang X, Duan W, Wang Q, Xu H, Zheng J, Zhao R, Zhu L, Dong Y, Lu L, Chen Y, Long J, Zheng S, Wang W, You H, Jia J*, Ou X*, Huang J.Non-HFE mutations in haemochromatosis in China: combination of heterozygous mutations involving HJV signal peptide variants. Journal of Medical Genetics.2018.55(10).650-660.SCI |
50. 吴晓宁,张伟,周家玲,王麟,孙亚朦,孟彤彤,王晓明,尤红,欧晓娟,贾继东*.基线HBVDNA水平不影响代偿期乙型肝炎肝硬化患者抗病毒治疗后的临床转归.临床肝胆病杂志.2018.34(8).1678-1682.核心期刊 |
51. 段维佳,欧晓娟,马红,王晓明,王宇,赵新颜,王倩怡,贾继东*.抗sp100和抗gp210在原发性胆汁性胆管炎中的诊断和临床意义.临床和实验医学杂志.2018.17(15).1579-1581.核心期刊 |
52. Shan S, Cui F, Jia J*.How to control highly endemic hepatitis B in Asia.Liver International.2018.38(Suppl 1).122-125.SCI |
53. Wang L, Wang B, You H, Wu X, Zhou J, Ou X, Jia J*.Platelets' increase is associated with improvement of liver fibrosis in entecavir-treated chronichepatitis Bpatients with significant liver fibrosis.Hepatology International.2018.12(3).237-243.SCI |
54. He T, Bai Y , Cai H, Ou X, Liu M, Yi W , Jia J*.Safety and efficacy of lamivudine or telbivudine started in early pregnancy for mothers with active chronic hepatitis B.Hepatology International.2018.12(2).118-125.SCI |
55. Wu S, Kong Y, Piao H, Jiang W, Xie W, Chen Y, Lu L, Ma A, Xie S, Ding H, Shang J, Zhang X, Feng B, Han T, Xu X, Huo L, Cheng J, Li H, Wu X, Zhou J, Sun Y, Ou X, Zhang H, You H, Jia J*.On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis.Liver International.2018.38(6).1045-1054.SCI |
56. Zeng N, Zou C, He Z, Ma H, Ou X, You H, Kong Y*, Jia J*.Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China.International Journal of Infectious Diseases.2018.67.58-64.SCI |
57. Duan W, Ou X, Wang X, Wang Y, Zhao X, Wang Q, Wu X, Zhang W, Ma H, You H, Jia J*.Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.Revista Espanola de Enfermedades Digestivas.2018.110(9).557-563.SCI |
58. Wang L,Liu T,Zhou J,You H,Jia J*.Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy.Hepatology Research.2018.48(3).E283-E290.SCI |
59. 孙亚朦,周家玲,王麟,吴晓宁,陈永鹏,朴红心,陆伦根,蒋伟,徐有青,封波,南月敏,谢雯,陈国凤,郑欢伟,李海,丁惠国,刘晖,吕福东,邵晨,王泰龄,欧晓娟,王冰琼,陈姝延,尤红,贾继东*.慢性乙型肝炎抗病毒治疗后肝纤维化逆转的病理定性评估.中华肝脏病杂志.2017.25(11).819-826.核心期刊 |
60. 张伟,贾继东*.肝纤维化的发病机制及治疗新靶点.临床肝胆病杂志.2017.33(3).409-412.核心期刊 |
61. 王宇,欧晓娟,贾继东*.高动力循环在肝硬化疾病进展中的重要性及其治疗策略.中华肝脏病杂志.2017.25(7).544-547.核心期刊 |
62. Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, Lu L, Jiang W, Xu Y, Feng B, Nan Y, Xie W, Chen G, Zheng H, Li H, Ding H, Liu H, Lv F, Chen Shao, Wang T, Ou X, Wang B, Chen S, Wee A, Theise ND*, You H*, Jia J*..New Classification of Liver Biopsy Assessment for Fibrosis in Chronic Hepatitis B Patients Before and After Treatment.Hepatology.2017.65(5).1438-1450.SCI |
63. Chen S, Duan W, You H, Jia J*..A brief review on prognostic models of primary biliary cholangitis.Hepatology International.2017.11(5).412-418.SCI |
64. 汤雯,王宇,赵新颜,王晓明,欧晓娟,贾继东*.门静脉血栓对肝硬化患者预后的影响.临床肝胆病杂志.2017.33(3).466-471.核心期刊 |
65. Cong M, Zhao W, Liu T, Wang P, Fan X, Zhai Q, Bao X, Zhang D, You H, Kisseleva T, Brenner DA, Jia J*, Zhuang H*.Protective effect of human serum amyloid P on CCl4-induced acute liver injury in mice.International Journal of Molecular Medicine.2017.40(2).454-464.SCI |
66. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J*.Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial..Hepatology.2008.47(2).447-454. .SCI |
67. Jia JD, Bauer M, Sedlaczek N, Herbst H, Ruehl M, Hahn EG, Riecken EO, Schuppan D..Modulation of collagen XVIII/endostatin expression in lobular and biliary rat liver fibrogenesis.Journal of hepatology.2001.35(3).386-91.SCI |
68. Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, Riecken EO, Schuppan D*..Antifibrotic effects of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen a1(I) and TIMP-1.Journal of hepatology.2001.35(3).392-398.SCI |